ScandiBio Therapeutics

ScandiBio Therapeutics is a Stockholm-based pharmaceutical company developing AI-driven drugs that target mitochondrial dysfunction, a factor implicated in neurodegenerative disorders and metabolic syndromes. Its lead product has entered a randomized, double-blind, placebo-controlled Phase III clinical trial in Turkey for patients with mild, moderate, and severe Alzheimer's disease, and has also completed Phase II trials in fatty liver patients and Phase III trials in COVID-19 patients. The company was founded by scientists affiliated with KTH Royal Institute of Technology, Karolinska Institutet, Sahlgrenska University Hospital, and King's College London.